Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition

Journal of Nutritional Biochemistry

Volumn 18, Issue 3, 2007, Pages 184-195

  Cave, Matthew ^a   Deaciuc, Ion ^a   Mendez, Christian ^a   Song, Zhenyuan ^a   Joshi Barve, Swati ^a   Barve, Shirish ^a   McClain, Craig ^a  

^a UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

Author keywords

Industrial toxins; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; BETAINE; METHIONINE; PIOGLITAZONE; S ADENOSYLMETHIONINE; TAMOXIFEN; TETRAHYDROLIPSTATIN; ZINC;

ADULT; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ARTICLE; CASE REPORT; CLINICAL TRIAL; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; EXERCISE; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; OBESITY; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; UNITED STATES; WEIGHT REDUCTION;

BETAINE; CYTOKINES; DIETARY SUPPLEMENTS; ENVIRONMENTAL EXPOSURE; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIVER; LIVER CIRRHOSIS; METABOLIC SYNDROME X; METHIONINE; MIDDLE AGED; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; S-ADENOSYLMETHIONINE; UNITED STATES; VITAMIN E; XENOBIOTICS; ZINC;

ZEA MAYS;

EID: 33846821856     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2006.12.006     Document Type: Article

References (106)

1. Westwater J.O., and Fainer D. Liver impairment in the obese. Gastroenterology 34 4 (1958) 686-693
2. Adler M., and Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67 5 (1979) 811-816
3. Ludwig J., Viggiano T.R., McGill D.B., and Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 7 (1980) 434-438
4. Louthan M.V., Joshi-Barve S., and McClain C.J. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 147 6 (2005) 835-838
5. McClain C.J., Mokshagundam S.P.L., Barve S.S., Song Z., Hill D.B., Chen T., et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol 34 1 (2004) 67-79
6. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 5 (2003) 1202-1219
7. Hubscher S.G. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 16 11 (2004) 1107-1115
8. Klein S., Wadden T., and Sugerman H.J. AGA technical review on obesity. Gastroenterology 123 3 (2002) 882-932
9. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 13 (2006) 1549-1555
10. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 10 (2004) 2444-2449
11. Bray G.A., Nielsen S.J., and Popkin B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79 4 (2004) 537-543
12. Solga S., Alkhuraishe A.R., Clark J.M., Torbenson M., Greenwald A., Diehl A.M., et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49 10 (2004) 1578-1583
13. Kennedy E.T., Bowman S.A., and Powell R. Dietary-fat intake in the US population. J Am Coll Nutr 18 3 (1999) 207-212
14. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 4 (2003) 1008-10017
15. Strauss R.S., Barlow S.E., and Dietz W.H. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 136 6 (2000) 727-733
16. Michailova A., Kuneva T., and Popov T. A comparative assessment of liver function in workers in the petroleum industry. Int Arch Occup Environ Health 71 Suppl (1998) S46-S49
17. Barberino J.L., Carvalho F.M., Silvany-Neto A.M., Cotrim H.P., Goes R.C., Rosa H., et al. Liver changes in workers at an oil refinery and in a reference population in the state of Bahia, Brazil. Rev Panam Salud Publica 17 1 (2005) 30-37
18. Fong Y., and Bentrem D.J. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243 1 (2006) 8-9
19. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 5 (2003) 960-967
20. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 6 (2004) 1387-1395
21. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 4 (2004) 820-826
22. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20 6 (1989) 594-598
23. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., and Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 6 (2002) 1349-1354
24. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 6 (1999) 1413-1419
25. Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., and Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 5 (2006) 1145-1151
26. Cortez-Pinto H., de Moura M.C., and Day C.P. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44 1 (2006) 197-208
27. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
28. Sumida Y., Nakashima T., Yoh T., Furutani M., Hirohama A., Kakisaka Y., et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 38 (2003) 32-38
29. Morrow J.D. Is oxidant stress a connection between obesity and atherosclerosis?. Arterioscler Thromb Vasc Biol 23 (2003) 368-370
30. Emery M.G., Fisher J.M., Chien J.Y., Kharasch E.D., Dellinger E.P., Kowdley K.V., et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38 (2003) 428-435
31. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 12 (2004) 1752-1761
32. Pessayre D., Berson A., Fromenty B., and Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 21 1 (2001) 57-69
33. McClain C.J., Barve S., Deaciuc I., Kugelmas M., and Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 19 (1999) 205-219
34. Schulze-Osthoff K., Bakker A.C., Vanhaesebroeck B., Beyaert R., Jacob W.A., and Fiers W. Cytotoxic activity of TNF is mediated by early damage of mitochondrial functions. J Biol Chem 267 (1992) 5317-5323
35. Rashid A., Wu T.C., Huang C.C., Chen C.H., Lin H.Z., Yang S.Q., et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 29 4 (1999) 1131-1138
36. Cortez-Pinto H., Chatham J., Chacko V.P., Arnold C., Rashid A., and Diehl A.M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282 17 (1999) 1659-1664
37. McClain C.J., and Cohen D.A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 9 (1989) 349-351
38. McClain C.J., Song Z., Barve S.S., Hill D.B., and Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 287 3 (2004) G497-G502
39. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
40. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., and Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 94 6 (1997) 2557-2562
41. Eastin C.E., McClain C.J., Lee E.Y., Bagby G.J., and Chawla R.K. Choline deficiency augments and antibody to tumor necrosis factor-a attenuates endotoxin-induced hepatic injury. Alcohol Clin Exp Res 21 (1997) 1037-1047
42. Chawla R., Watson W., Eastin C., Lee E., Schmidt J., and McClain C.J. S-adenosylmethionine (AdoMet) deficiency and tumor necrosis factor (TNF) in lipopolysaccharide (LPS) induced hepatic injury. Am J Physiol 275 (1998) G125-G129
43. Dela Pena A., Leclercq I., Field J., George J., Jones B., and Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129 5 (2005) 1663-1674
44. Kugelmas M., Hill D.B., Vivian B., Marsano L., and McClain C.J. Cytokines and NASH: effects of lifestyle modification and vitamin E. Hepatology 38 2 (2003) 413-419
45. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
46. Valenti L., Francanzani L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 122 (2002) 274-280
47. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
48. Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 200-206
49. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
50. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 1 (2005) 117-121
51. Chawla R.K., Lewis F.W., Kutner M.H., Bate D.M., Roy R.G., and Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 87 (1984) 770-776
52. Mato J.M., Alvarez L., and Corrales J. S-adenosylmethionine and the liver. In: Arias I.M. (Ed). Liver: Biology and Pathobiology (1997), Raven Press, New York 461-470
53. Duce A.M., Ortiz P., Cabrero C., and Mato J.M. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 8 (1998) 65-68
54. Mato J.M., Alvarez L., Ortiz P., and Pajares M.A. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 73 (1997) 265-280
55. Sanchez-Gongora E., Ruiz F., Mingorance J., An W., Corrales F.J., and Mato J.M. Interaction of liver methionine adenosyltransferase with hydroxyl radical. FASEB J 11 (1997) 1013-1019
56. Lu S.C., Alvarez L., Huang Z.Z., Chen L., An W., Corrales F.J., et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 98 (2001) 5560-5565
57. Song Z., Zhou Z., Uriarte S., Wang L., Kang Y.J., Chen T., et al. S-adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology 40 (2004) 989-997
58. Ji C., and Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124 (2003) 1488-1499
59. Barak A.J., Beckenhauer H.C., Mailliard M.E., Kharbanda K.K., and Tuma D.J. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr 133 (2003) 2845-2848
60. Schwahn B., and Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 1 (2001) 189-201
61. Marceau P., Biron S., Hould F.S., Marceau S., Simard S., Thung S.N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84 (1999) 1513-1517
62. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
63. Knobler H., Schattner A., Zhornicki T., Malnick S.D., Keter D., Sokolovskaya N., et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 92 (1999) 73-79
64. Cortez-Pinto H., Camilo M.E., Baptista A., De Oliveira A.G., and De Moura M.C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 18 (1999) 353-358
65. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
66. Cave M., Louthan M.V., and McClain C.J. Nonalcoholic fatty liver disease. Gastroenterology board review manual. Hosp Physician 11 1 (2005) 1-12
67. Banerji M.A., Buckley M.C., Chaiken R.L., Gordon D., Lebovitz H.E., and Kral J.G. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 19 (1995) 846-850
68. Ryysy L., Hakkinen A.M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49 (2000) 749-758
69. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003) 1364-1370
70. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
71. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 16 (1998) 663-678
72. Koteish A., and Diehl A.M. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 679-690
73. Bjorkegren J., Beigneux A., Bergo M.O., and Maher J.J. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 277 (2002) 5476-5483
74. Jandacek R.J., Anderson N., Liu M., Zheng S., Yang Q., and Tso P. Effect of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol 288 (2004) G292-G299
75. Rozman T., Rozman K., and Smith G.S. Relationship of body weight to disposition of hexachloronbenzene. Toxicol Lett 18 (1983) 171-175
76. Cotrim H.P., Andrade Z.A., Parana R., Portugal M., Lyra L.G., and De Freitas L.A. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 19 (1999) 299-304
77. Cotrim H.P., DeFreitas L.A., Freitas C., Braga L., Sopusa R., Carvalho F., et al. Clinical and histopathological features of NASH in workers exposed to chemicals with or without associated metabolis conditions. Liver Int 24 (2004) 131-135
78. Guidorizzi de Siqueira A.C., Cotrim H.P., Rocha R., Carvalho F.M., de Freitas L.A., Barreto D., et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 17 8 (2005) 837-841
79. -/- mice. Toxicol Sci 88 (2005) 95-102
80. Treiber G., Cssepregi A., and Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis 23 (2005) 6-10
81. Bidlack W.R., Brown R.C., and Mohan C. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc 45 (1986) 142-148
82. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 1 (1997) 103-107
83. Pate R.R., Pratt M., Blair S.N., Haskell W.L., Macera C.A., Bouchard C., et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273 5 (1995) 402-407
84. Clark J.M., Alkhuraishi A.R., Solga S.F., Alli P., Diehl A.M., and Magnuson T.H. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13 7 (2005) 1180-1186
85. Andersen T., Gluud C., Franzmann M.B., and Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 2 (1991) 224-229
86. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23 8 (2006) 1143-1151
87. Tovar A.R., Torre-Villalvazo I., Ochoa M., Elias A.L., Ortiz V., Aguilar-Salinas C.A., et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 46 9 (2005) 1823-1832
88. Ruhl C.E., and Everhart J.E. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128 1 (2005) 24-32
89. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136 (2000) 734-738
90. Vajro P., Mandato C., Franzese A., Ciccimarra E., Lucariello S., Savoia M., et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 38 (2004) 48-55
91. Hasegawa T., Yoneda M., Nakamura K., Makino I., and Terano A. Plasma transforming growth factor β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15 (2001) 1667-1672
92. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004) 1107-1115
93. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46
94. McClain C.J., Hill D.B., Song Z., Chawla R., Watson W., Chen T., et al. S-adenosylmethionine, cytokines and alcoholic liver disease. Alcohol 27 3 (2002) 185-192
95. Song Z., Zhou Z., Chen T., Hill D., Kang J., Barve S., et al. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice small star, filled. J Nutr Biochem 14 10 (2003) 591-597
96. Song Z., Barve S., Chen T., Nelson W., Uriarte S., Hill D., et al. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes. Am J Physiol Gastrointest Liver Physiol 284 6 (2003) G949-G955
97. Mato J.M., Camara J., Fernandez de Paz J., Caballeria L., Coll S., Caballero A., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30 6 (1999) 1081-1089
98. Craig S.A. Betaine in human nutrition. Am J Clin Nutr 80 3 (2004) 539-549
99. Barak A.J., Beckenhauer H.C., Mailliard M.E., Kharbanda K.K., and Tuma D.J. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr 133 9 (2003) 2845-2848
100. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvestre P.B., and Lindor K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96 9 (2001) 2534-2536
101. McClain C.J., Antonow D.R., Cohen D.A., and Shedlofsky S. Zinc metabolism in alcoholic liver disease. Alcohol Clin Exp Res 10 (1986) 582-589
102. Gaetke L., McClain C.J., Talwalkar R., and Shedlofsky S. Effects of endotoxin on zinc metabolism in human volunteers. Am J Physiol 272 (1997) E952-E956
103. Kang Y.J., and Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 26 (2005) 391-404
104. Brewer G.J., Yuzbasiyan-Gurkan V., and Young A.B. Treatment of Wilson's disease. Semin Neurol 7 (1987) 209-220
105. Zhou Z., Wang L., Song Z., Lambert J.C., McClain C.J., and Kang Y.J. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol 163 (2003) 1137-1146
106. Lambert J.C., Zhou Z., Wang L., Song Z., McClain C.J., and Kang Y.J. Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. J Pharmacol Exp Ther 305 (2003) 880-886